Tamoxifen (correction)
Executive Summary
Tamoxifen is a selective estrogen receptor modulator. An article about new indications for Lilly's osteoporosis drug Evista described tamoxifen as an aromatase inhibitor. Additionally, Lilly's arzoxifene is in Phase III studies for prevention of invasive breast cancer and treatment of osteoporosis - Phase III studies for the treatment of metastatic breast cancer are not underway (1"The Pink Sheet" Sept. 24, 2007, p. 16)...
You may also be interested in...
Evista Gains Breast Cancer Risk Reduction Claim But Adds Black Box Warning
FDA's approval of Lilly's osteoporosis drug Evista for two preventative cancer treatment indications expands the drug's market into the oncology field, while placing it at odds with competing osteoporosis products because of new risk labeling
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.